共 39 条
[2]
ABRAMSON SB, 1988, HOSP PRACT, V23, P45
[4]
COMPLEMENT ACTIVATION DURING SYSTEMIC LUPUS-ERYTHEMATOSUS - C3A AND C5A ANAPHYLATOXINS CIRCULATE DURING EXACERBATIONS OF DISEASE
[J].
ARTHRITIS AND RHEUMATISM,
1986, 29 (09)
:1085-1089
[5]
BEVALACQUA M, 1993, ANN REV INFLAMMATION, V11, P767
[6]
DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS
[J].
ARTHRITIS AND RHEUMATISM,
1992, 35 (06)
:630-640
[7]
ACTIVATION OF THE ALTERNATIVE COMPLEMENT PATHWAY ACCOMPANIES DISEASE FLARES IN SYSTEMIC LUPUS-ERYTHEMATOSUS DURING PREGNANCY
[J].
ARTHRITIS AND RHEUMATISM,
1992, 35 (01)
:55-61
[8]
ASSESSMENT OF DISEASE-ACTIVITY AND IMPENDING FLARE IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS - COMPARISON OF THE USE OF COMPLEMENT SPLIT PRODUCTS AND CONVENTIONAL MEASUREMENTS OF COMPLEMENT
[J].
ARTHRITIS AND RHEUMATISM,
1992, 35 (09)
:1028-1037
[9]
SURFACE EXPRESSION OF GP165/95, THE COMPLEMENT RECEPTOR CR3, AS A MARKER OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS
[J].
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY,
1988, 46 (01)
:141-149

